TABLE II.
Selected Antifungal Prophylaxis Trials
| Prophylaxis | Design | # of Patients (# of pediatric) | Disease/procedure | Control outcome | Intervention outcome | Reference |
|---|---|---|---|---|---|---|
| Fluconazole | DB, PC, MC | 356 (?)a | Auto & Allo HCT | 16% at 50 days (placebo) | 3% at 50 days | Goodman et al. [25] |
| Fluconazole | DB, PC, SC | 300 (?)a | Auto & Allo HCT | 18% at 75 days (placebo) | 7% at 75 days | Slavin et al. [26] |
| Amphotericin B | OL, MC | 355 (0) | Auto & Allo HCT | 9% (fluconazole) | 14% | Wolff et al. [30] |
| LFAB | OL Pilot | 57 (57) | Allo HCT | NA | 0% at 100 days | Roman et al. [31] |
| Itraconazole | OL, SC | 304 (5)a | Allo HCT | 15% (fluconazole) | 7% | Marr et al. [37] |
| Voriconazole | DB, MC | 600 (51) | Allo HCT | 11% (fluconazole) at 6 months | 7% at 6 months | Wingard et al. [28] |
| Posaconazole | OL, MC | 602 (?)a | AML/MDS | 11% (flucon or itra) at 100 days | 5% at 100 days | Cornely et al. [27] |
| Micafungin | DB, MC | 882 (84) | Auto & Allo HCT | 1.6% (fluconazole) at 70 days | 2.4% at 70 days | van Burik et al. [29] |
| Caspofungin | OL, SC | 200 (0) | AML/MDS | 6% (itraconazole) | 6% | Mattiuzzi et al. [50] |
| Caspofungin | Retrospective | 123 (0) | Auto & Allo HCT | NA | 7.3% at 100 days | Chou et al. [51] |
a
Only patients >12 years of age were eligible; DB, Double-blind; PC, Placebo-controlled; MC, Multi-center; OL, Open-label; SC, Single-center; NA, Not Applicable; AML, Acute Myeloblastic Leukemia; MDS, Myelodysplastic Syndrome.